TellDx-Enabled Circulating Tumor Cell Analysis Predicts Response to DLL3-Targeted Therapy in Small Cell Lung Cancer

— Study Results Support the use of TellDx to Personalize Cancer Care Management –

— Clinical study published in Cancer Discovery —

Excerpt from the Press Release:

ANDOVER, Mass., Jan. 14, 2026 (GLOBE NEWSWIRE) — TellBio, Inc., a medical technology company focused on revolutionizing the management of cancer through its unique and proprietary circulating tumor cell (CTC) technology, the TellDx CTC System, announces the publication of data demonstrating that analysis of circulating tumor cells using TellDx can predict patient response to the DLL3-targeting bispecific antibody tarlatamab in small cell lung cancer (SCLC). The paper, “Circulating Tumor Cells Predict Response to the DLL3-targeting Bispecific Antibody Tarlatamab,” was published in Cancer Discovery (DOI 10.1158/2159-8290.CD-25-1483).

“This publication highlights the power of our unique circulating tumor cell analysis to reveal clinically actionable biology that cannot be captured through traditional tissue-based testing. The ability to non-invasively stratify patients and monitor response at the single-cell level has important implications not only for DLL3-targeted therapies, but for the broader management of cancer,” said Annie Partisano, PharmD, MS, Senior Vice President and Head of Operations, TellBio, Inc.

The study, led by investigators at Massachusetts General Hospital (MGH) and Harvard Medical School, shows that quantifying DLL3 expression on circulating tumor cells isolated with TellDx prior to treatment accurately identifies patients most likely to benefit from tarlatamab therapy.

Click the button below to read the entire Press Release:

Continue Reading The Press Release